ADXS (Ayala Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ayala Pharmaceuticals Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Ayala Pharmaceuticals's Dividend Payout Ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Ayala Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:

ADXS's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.45
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-03-23), the Dividend Yield % of Ayala Pharmaceuticals is 0.00%.

Ayala Pharmaceuticals's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Ayala Pharmaceuticals Dividend Payout Ratio Historical Data

The historical data trend for Ayala Pharmaceuticals's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ayala Pharmaceuticals Dividend Payout Ratio Chart

Ayala Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Ayala Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ayala Pharmaceuticals's Dividend Payout Ratio

For the Biotechnology subindustry, Ayala Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ayala Pharmaceuticals's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Ayala Pharmaceuticals's Dividend Payout Ratio falls into.

Ayala Pharmaceuticals Dividend Payout Ratio Calculation

Ayala Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-7.99
	=	N/A

Ayala Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-2.081
	=	N/A

Ayala Pharmaceuticals (OTCPK:ADXS) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Ayala Pharmaceuticals Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Ayala Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (OTCPK:ADXS) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852

Website

https://www.ayalapharma.com

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.

Executives

Yair Chaim Schindel	other: shareholder of 10% holder	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
Roni Mamluk	director, officer: CEO	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
Gary B. Gordon	officer: Chief Medical Officer	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Harel Insurance Co Ltd	10 percent owner	ABBA HILLEL 3, RAMAT GAN L3 5211802
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Maimon Yossi	officer: CFO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Harel Insurance Investments & Financial Services Ltd.	10 percent owner	HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118
Todd Sone	director	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104